News | July 24, 2025
Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr
Revenue increased 11.4 per cent to Rs. 8,545 crore
Revenue increased 11.4 per cent to Rs. 8,545 crore
Upgrades 2025 full-year CDMO sales and margin outlook
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
The company showcased three core programs developed through this platform
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Annual EBITDA margin expands by 170 basis points
Akums invested Rs. 272 crore in capital expenditure during FY25
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Subscribe To Our Newsletter & Stay Updated
